Lipoprotein(a) further invalidates Friedewald formula.

92% had THCA concentrations 30 zgfL. Of the 97 specimens that screened negative at 100 pgfL, 80% had quantitative values for THCA of 30 p gfL. This suggests that reducing the screening cutoff to 50 pgIL will not result in laboratories being flooded with large numbers of specimens for which the THCA concentrations are within 20% of the 15 ig/L confirmation cutoff. The THCA-positive detection rate for the 30402 specimens analyzed at the 100 p.g/L cutoff was 0.94%. This rate was increased to 1.26% by lowering the cutoff to 50 g’L. We conclude that the effectiveness of drug detection programs will be enhanced by reducing the screening cutoff for cannabinoids. The cost-effectiveness of a company’s drug testing program is often determined by calculating the cost per positive test. However, the true expense of drug testing is based on the cost of collection, transportation, laboratory analyses, and Medical Review Officer services. The additional specimens screened positive will result in an increased laboratory cost for the additional confirmations, but the other costs involved in drug testing will remain the same. Therefore, the cost-effectiveness of a company’s drug testing program based on the cost per positive specimen will actually decrease because of the increased detection rate for cannabinoid use. Any increase in cost due to additional confirmations will be offset by economic savings to employers because of financial liabilities associated with the employment of drug users.